Avanafil is a selective small-molecule drug used in the treatment of erectile dysfunction (ED). It belongs to a well-defined class of medicines known as phosphodiesterase type 5 (PDE5) inhibitors, which enhance blood flow by supporting normal vascular responses during sexual stimulation.

At the molecular level, Avanafil is designed for high selectivity toward the PDE5 enzyme, which plays a central role in regulating blood flow in penile tissue. Its targeted activity allows for rapid onset of action while minimizing interaction with related enzymes, contributing to a favorable tolerability profile.

Because Avanafil is used on demand and relies on predictable pharmacokinetics, molecular purity, consistency, and stability are critical. These characteristics help ensure reliable performance, patient confidence, and alignment with regulatory quality standards. Avanafil is recognized for its role in modern urology and men’s health treatment approaches.

Prescribing Information

Prescribing information provides authoritative guidance on approved indications, dosing recommendations, administration instructions, contraindications, and safety considerations.

Clinical Trial Details

Avanafil has been evaluated in multiple randomized, placebo-controlled clinical trials that demonstrated its efficacy and safety in men with erectile dysfunction of varying severity and underlying causes.

FDA Approval Status

Avanafil is approved by the U.S. Food and Drug Administration for the treatment of erectile dysfunction in adult men. It is marketed under the brand name Stendra®, originally developed by VIVUS.